Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.

NCT01584297 is registered in ClinicalTrials.gov with Grupo Español de Tumores Huérfanos e Infrecuentes as lead sponsor.

NCT NCT01584297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01584297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.
Lead sponsor
Grupo Español de Tumores Huérfanos e Infrecuentes
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2012
Completion date
November 30, 2014
Enrollment
6 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

granulosa cell tumour of the ovary